Article
Single copy of variant CYP2A6 alleles does not confer susceptibility to liver dysfunction in patients treated with coumarin.
International journal of clinical pharmacology and therapeutics - 1 Apr 2003
Burian M, Freudenstein J, Tegtmeier M, Naser-Hijazi B, Henneicke-von Zepelin H H, Legrum W
Abstract excerpt
OBJECTIVE: Coumarin, used in the treatment of chronic venous diseases, is mainly metabolized to non-toxic 7-hydroxy-coumarin by CYP2A6. At least, 3 variant alleles, CYP2A6*2, CYP2A6*3 and CYP2A6*4A, have been shown to encode catalytically defective proteins. Sporadic elevation of liver enzymes has been reported on the chronic administration ofcoumarin. We sought to determine if susceptibility to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
